Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2024 08:00 ET | Source: Fractyl Health, Inc.

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation
April 01, 2024 07:00 ET | Source: Fractyl Health, Inc.

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 01, 2024 06:00 ET | Source: Fractyl Health, Inc.

Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
March 12, 2024 14:06 ET | Source: Fractyl Health, Inc.

UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Fractyl Health today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
March 12, 2024 08:38 ET | Source: Fractyl Health, Inc.

Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Fractyl Health today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
February 20, 2024 08:38 ET | Source: Fractyl Health, Inc.

Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
February 01, 2024 20:08 ET | Source: Fractyl Health, Inc.

Fractyl Health Announces Pricing of Initial Public Offering

Fractyl Health (Nasdaq: GUTS), announces pricing of initial public offering.
January 05, 2024 07:48 ET | Source: Fractyl Health, Inc.

Fractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in Its Rejuva® GLP-1 Gene Therapy Platform

FRACTYL HEALTH ANNOUNCES NOMINATION OF RJVA-001 AS FIRST CLINICAL CANDIDATE IN ITS REJUVA® GLP-1 GENE THERAPY PLATFORM
December 14, 2023 05:45 ET | Source: Fractyl Health, Inc.

Fractyl Health Announces New Pooled Analysis From Revita® Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance Without Weight Regain Through at Least One Year Post-Revita Procedure

Fractyl Health Announces New Pooled Analysis From Revita Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance without Gain
December 11, 2023 08:38 ET | Source: Fractyl Health, Inc.

Fractyl Health Demonstrated That a Single Dose of a GLP-1-Based Pancreatic Gene Therapy Candidate (GLP-1 PGTx) Durably Maintained Weight Loss After Semaglutide Withdrawal in a Murine Model of Obesity at WCIRDC 2023 Annual Meeting

Fractyl Health presented preclinical findings from its Rejuva® gene therapy platform at the WCIRD23 Annual Meeting.